BURLINGTON, Mass., Oct. 10, 2017 /PRNewswire/ -- MilliporeSigma will welcome world-renowned academic researchers, technology experts and industry entrepreneurs to discuss advances and opportunities in some of the most exciting areas of life science on Wednesday, October 11, 2017, 10 a.m. at the company's new Life Science Center in Burlington.
"I love science," said Udit Batra, CEO, MilliporeSigma. "I get to be a student again and I am looking forward to the many thought-provoking conversations that will take place. Every program is very exciting — from microbiome, big data and genome editing to biosecurity and e-commerce. It is about convening some of the greatest contributors and leaders in their scientific fields to discuss, listen and learn."
MIT's Dr. Rosalind Picard, founder and director of the Affective Computing research group at the MIT Media Lab, will give the keynote address, "Look. See. Solve," on problem solving and the culture of focus and endurance.
Other speakers include Fortune Editor-in-Chief Clifton Leaf; Dr. Peter Hotez, founding dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine; Bernard Munos, founder of the InnoThink Center for Research in Biomedical Innovation; Dr. Makedonka Mitreva, associate professor in both departments of Medicine and Genetics, Assistant Director of the McDonnell Genome Institute at the Washington University School of Medicine; Dr. Laurie Leshin, president of Worcester Polytechnic Institute; Peter Abair, executive director of the MassBioEd Foundation; Dr. Darryl Williams, dean of undergraduate education and director of the Center for STEM Diversity at Tufts University; Dr. Charles Gersbach, Rooney Family associate professor of Biomedical Engineering at Duke University; Liran Belenzon, CEO and co-founder of BenchSCI; Dr. Konstantin Konstantinov, senior vice president of manufacturing and process sciences at Codiak Biosciences; Dr. Christopher Bouton, CEO of Vyasa and Dr. Nessan Bermingham, CEO and founder of Intellia Therapeutics.
Sessions will also be held on genome editing, microbiome, big data & biology and STEM education.
MilliporeSigma's new, 280,000-square-foot Life Science Center – Burlington, located at 400 Summit Drive, is a global hub for scientific advancement and customer collaboration. The new campus features an M Lab™ Collaboration Center, and a BioReliance® End-to-End Biodevelopment Center, which will open on the campus by year-end.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.